Level of protection | Animal name | Virological outcome | Interpretation | Immunogens | Challenge viruses (challenge route) | Enrolled in study |
---|---|---|---|---|---|---|
Complete | ROb-12 | Aviremic | Cryptic infection | HIV-C gp160 and gp145 + SIV Gag overlapping synthetic peptides (OSP)+ HIV Tat OSP+ SIV Nef OSP | Multiple low-doses with SHIV-2873Nip (intrarectal) [14] | unpublished |
RAt-9 | Aviremic | Cryptic infection | HIV-C gp160 + SIV Gag-Pol particles + HIV Tat | Single low-dose with SHIV-1157ip (oral) and single high-dose with SHIV-1157ipd3N4 (intrarectal) [15] | ||
RQe-10 | Aviremic | Sterilizing immunity | Listeria monocytogenes expressing SIV gag + Ad5hr encoding SIV gag + HIV-C gp160 + HIV Tat | Multiple low-doses with SHIV-1157ipEL-p (intrarectal) [13] | [11] | |
RRi-11 | Aviremic | Sterilizing immunity | HIV-C gp160 + SIV Gag-Pol particles + HIV Tat | Multiple low-doses and one high-dose with SHIV-1157ipEL-p (intrarectal) [13] | [12] | |
RTr-11 | Aviremic | Cryptic infection | ||||
Partial | RBr-11 | Lower peak viremia | Chronic systemic infection | |||
RGe-11 | Aviremic during low-dose challenges | 2 low-level blips (<104 copies/ml) | ||||
None | RDo-11 | No protection | Chronic systemic infection |